Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $50.0M | $0.00 | — |
| Revenue growth | — | -100.0% | — |
| Operating income | $16.1M | -$50.9M | -$68.1M |
| Operating margin | 32.2% | — | — |
| Net income | $22.7M | -$42.3M | -$60.0M |
| Net margin | 45.4% | — | — |
| EPS (diluted) | $0.08 | -$2.18 | -$2.17 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | $19.3M | -$32.8M | -$55.3M |
| Capital expenditures | $414K | $514K | $231K |
| Free cash flow | $18.9M | -$33.4M | -$55.5M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $15.5M | $21.9M | $75.6M |
| Total assets | $130M | $213M | $277M |
| Total liabilities | $5.70M | $14.8M | $15.7M |
| Shareholders' equity | -$67.9M | $198M | $261M |
| Retained earnings | -$75.1M | -$117M | -$177M |
| Shares (wtd avg diluted) | 3.40M | 19.4M | 27.7M |
Every figure is extracted from Contineum Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.